The p53 tumor suppressor is activated in response to a variety of cellular stress signals, including DNA damage. Its ability to facilitate growth arrest and/or cell death in response to such signals is believed to be the basis for its tumor suppressor function (see references 5, 16, 22, and 27 for reviews). However, specific in vivo signals that trigger tumor suppression have not been identified. Sixty to eighty percent of the spontaneous malignancies in p53-deficient mice are thymic lymphomas (13, 17), indicating that natural thymocyte events signal p53 tumor suppression. The favored hypothesis is that flawed T-cell receptor (TCR) gene recombination events signal p53-dependent elimination of damaged cells (15, 17, 24, 28) . p53 inactivation would thus facilitate the survival of cells carrying tumorigenic mutations. This hypothesis is consistent with several observations, including that (i) double-strand DNA breaks (DSBs) trigger p53 responses (29), (ii) p53 is required for DNA damage-induced thymocyte apoptosis (11, 23), (iii) thymic lymphomas induced by p53 deficiency are clonal, indicating that additional tumorigenic events are required (38), and (iv) in scid mice, which accumulate V(D)J breaks, lymphoid malignancies are accelerated by p53 deficiency (15, 28). Since V(D)J translocations are frequently associated with oncogene activation in human and mouse lymphoid tumors, it is reasonable to suspect that these events may be involved in tumorigenesis in the absence of p53-mediated surveillance.
The p53 tumor suppressor is activated in response to a variety of cellular stress signals, including DNA damage. Its ability to facilitate growth arrest and/or cell death in response to such signals is believed to be the basis for its tumor suppressor function (see references 5, 16, 22 , and 27 for reviews). However, specific in vivo signals that trigger tumor suppression have not been identified. Sixty to eighty percent of the spontaneous malignancies in p53-deficient mice are thymic lymphomas (13, 17) , indicating that natural thymocyte events signal p53 tumor suppression. The favored hypothesis is that flawed T-cell receptor (TCR) gene recombination events signal p53-dependent elimination of damaged cells (15, 17, 24, 28) . p53 inactivation would thus facilitate the survival of cells carrying tumorigenic mutations. This hypothesis is consistent with several observations, including that (i) double-strand DNA breaks (DSBs) trigger p53 responses (29) , (ii) p53 is required for DNA damage-induced thymocyte apoptosis (11, 23) , (iii) thymic lymphomas induced by p53 deficiency are clonal, indicating that additional tumorigenic events are required (38) , and (iv) in scid mice, which accumulate V(D)J breaks, lymphoid malignancies are accelerated by p53 deficiency (15, 28) . Since V(D)J translocations are frequently associated with oncogene activation in human and mouse lymphoid tumors, it is reasonable to suspect that these events may be involved in tumorigenesis in the absence of p53-mediated surveillance.
V(D)J recombination affects TCR and immunoglobulin (Ig) DNA rearrangement in developing T and B cells to generate a variety of antigen receptor specificities. Normally this process occurs during specific stages of T-and B-cell differentiation to yield a single productive rearrangement per cell for each polypeptide component of the receptor. The initiating event in V(D)J recombination, the generation of specific DSBs, requires two recombination activating genes (RAGs), RAG-1 and RAG-2 (9, 31) . Mice deficient in either of these genes fail to undergo V(D)J recombination and are immunodeficient due to the lack of mature T and B cells (25, 37) . Thus, these mice provide an approach for assessing the role of V(D)J recombination in thymomagenesis associated with p53 deficiency. Here we examine the impact of inactivating V(D)J recombination on tumorigenesis by introducing RAG deficiencies and/or rearranged TCR transgenes into mice with a thymocyte p53 deficiency. Additionally, we analyze the chromosomes of p53-deficient thymomas for evidence of TCR translocations and other aberrations.
MATERIALS AND METHODS
Mice. RAG-1 Ϫ/Ϫ (C57BL/6J-sv/129), scid/scid (C57BL/6J), TgN(TcrLCMV) (B6D2), and p53 Ϫ/Ϫ (C57BL/6J) mice were from Jackson Laboratory, and RAG-2 Ϫ/Ϫ mice (129, SvEv) were from Taconic Laboratory. TgT⌬N mice (B6D2), previously referred to as TgLST1135, abundantly express the dl1135 simian virus 40 (SV40) large T antigen (T-Ag) in thymocytes under the regulation of the lymphotropic papovavirus transcriptional signals (38) . Although low levels of the transgene are also expressed in B cells, only thymic lymphoma develops in these mice (38) . The dl1135 protein (referred to here as T⌬N) binds p53 and the pRB family proteins and inactivates p53 in vivo (10, 24) . T⌬N is defective in transformation of cultured cells due to a deletion (residues 17 to 27) that inactivates an N-terminal transformation function (32) . The T⌬N transgene harbors a deletion in the small t antigen splice donor site and does not express SV40 small t antigen. With the exception of scid mice, PCR assays of tail DNA were used to screen mouse genotypes as previously described (17, 38) or according to Jackson Laboratory [Ͻhttp://www.jax.org/resources/documents/imr/protocols/TgN(Tcr-LCMV).htmlϾ]. RAG-1 alleles were identified by using two primer pairs: for RAG-1 wild type, RAG-1F (5Ј-CCA GTA GAT ACC ATT GCG AAG AGG-3Ј)  and RAG-1B (5Ј-CAC GTT CTG TGA ACC ATG CTC TAT C-3Ј); and for  RAG-1 knockout, RAG-1B and Neo-R (5Ј-CCG CTT CCA TTG CTC AGC  GG-3Ј) . PCR conditions were 35 cycles of 30 s at 94°C, 1 min at 59°C, and 1 min at 72°C. RAG-2 alleles were identified by using two primer pairs: for RAG-2 wild type, RAG-2A (5Ј-GGG AGG ACA CTC ACT TGC CAG TA-3Ј) and RAG-2B (5Ј-AGT CAG GAG TCT CCA TCT CAC TGA-3Ј); and for RAG-2 knockout, RAG-2B and Neo-2 (5Ј-AGG TGA GAT GAC AGG AGA TC-3Ј). PCR conditions were 35 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C. The scid mice were screened by using enzyme-linked immunosorbent assay (ELISA) detection of serum IgM, which is absent in scid mice (14) .
To FACS analysis. Thymoma cell type was determined by fluorescence-activated cell sorting (FACS) analysis using phycoerythrin (PE)-anti-CD90 (Thy-1.2) and fluorescein isothiocyanate (FITC)-anti-CD45R/B220 antibodies (PharMingen), and thymocyte distribution was determined by using FITC-anti-CD4 and PEanti-CD8 antibodies (PharMingen), as described previously (18) . The thymocyte proliferation index was determined by in vivo labeling with bromodeoxyuridine (BrdU) (Boehringer Mannheim) for 1 h after intraperitoneal injection (0.1 ml/10 g of body weight), isolation of thymocytes as described previously (24, 38) , and FACS analysis with FITC-anti-BrdU antibody (Boehringer Mannheim) and propidium iodide staining. The total thymocyte apoptotic index was determined by FACS using a modification of the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling assay (Cell Death Detection kit) as recommended by Boehringer Mannheim.
Karyotype and fluorescence in situ hybridization analyses. Minced mouse thymoma cells were harvested directly, using routine cytogenetics laboratory procedures for preparation of metaphase chromosomes (41) . Karyotypes were determined by standard Giemsa banding techniques (36) . Biotinylated mouse whole chromosome paint probes for chromosomes 6, 13, and 14 were used as instructed by the supplier (Oncor, Inc., Gaithersburg, Md.). These probes were obtained from flow-sorted mouse chromosomes and were optimized to hybridize only to target chromosomes. Hybridization to repetitive sequences was suppressed by including excess mouse repetitive DNA. Biotinylated probes were detected by incubation with rabbit antibiotin antibody, biotinylated anti-rabbit antibody, and streptavidin-FITC. Mouse chromosomes were counterstained with propidium iodide. Images of metaphases were captured by a charge-coupled device camera and analyzed with Smartcapture software (Vysis Inc., Downers Grove, Ill.).
RESULTS
Mice deficient in both RAG and p53 develop thymoma. We introduced RAG-1 or RAG-2 deficiency into mice lacking thymocyte p53 activity by using standard genetic crosses as outlined in Materials and Methods. Since T-cell tumorigenesis in p53 Ϫ/Ϫ mice is not fully penetrant and other complicating tumor types develop, in most experiments we used transgenic mice that express an SV40 T-Ag derivative, T⌬N, specifically in thymocytes (see Materials and Methods). This oncoprotein inactivates p53, and we previously showed that 100% of TgT⌬N mice develop exclusively thymic lymphoma at about 5 months of age (38) . Prior to 2 months of age, thymocyte distribution is normal and consists predominantly of CD4 CD8 double-positive (DP) thymocytes (38) . From 2 to 5 months, the thymus expands rapidly and consists increasingly of a single V␤ T-cell class high in cell surface CD3 and CD4 CD8 single positive, double negative, or DP (38) . This phenotype is dependent on a functional T-Ag p53-binding domain (40) , and T-cell tumors are indistinguishable from those induced by p53 gene inactivation (22a, 38) . Furthermore, preneoplastic TgT⌬N thymocytes are defective in irradiation-induced p53-dependent apoptosis (24) .
The high frequency and predictability of thymic lymphoma in TgT⌬N mice facilitate quantitative studies on the role of V(D)J recombination. However, in addition we generated p53 Ϫ/Ϫ mice deficient in RAG-2 to control for any unexpected effects of T⌬N. If V(D)J recombination is required for T-cell tumorigenesis in the absence of p53, inactivation of this process would inhibit tumorigenesis. TgT⌬N/RAG-1
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Ϫ/Ϫ mice were generated through standard backcrosses, and the timing and frequency of thymoma were measured. All of the mice became ill and were sacrificed and necropsied (Fig. 1A) . Thymic lymphoma had developed in the majority of RAG-deficient TgT⌬N mice, although the frequency was somewhat reduced (85% in TgT⌬N/ RAG-1 Ϫ/Ϫ mice and 83% in TgT⌬N/RAG-2 Ϫ/Ϫ mice [ Table  1 Ϫ/Ϫ tumors, including sarcoma, testicular tumors, and lymphoma (13, 17) .
obvious neoplasm (a phenotype also observed in mice with RAG deficiency alone [see the legend to Fig. 1]) . Thymoma developed in 55% of the p53 Ϫ/Ϫ RAG-2 ϩ/Ϫ mice (Fig. 1B) , a frequency lower than for TgT⌬N mice due to the development of other tumor types (as previously observed). Inactivation of V(D)J recombination did not reduce this frequency, as 67% of p53 Ϫ/Ϫ RAG-2 Ϫ/Ϫ mice developed thymoma ( Fig. 1B ; Table  1 ). FACS analysis of three TgT⌬N/RAG-1 Ϫ/Ϫ thymomas showed that cells were CD4 CD8 DP, CD3 negative, and V␤ negative, consistent with the fact that V(D)J recombination is inactive (data not shown). The high frequency of thymoma in p53 and RAG-deficient mice indicates that V(D)J recombination, and T-cell differentiation in general, is dispensable for T-cell tumorigenesis.
Although most RAG-deficient TgT⌬N mice developed thymoma, tumors arose more slowly or with longer latency, based on extended survival ( Fig. 1A ; Table 1 ). All of the control TgT⌬N/RAG-1 ϩ/Ϫ mice developed thymoma with a t 50 (time at which half of the animals were sacrificed or died due to overt illness) of 165 days, similar to that previously reported for TgT⌬N mice (38) . The t 50 for TgT⌬N/RAG-1 Ϫ/Ϫ mice, however, was 238 days. Thymoma developed with reduced latency in control TgT⌬N/RAG-2 ϩ/Ϫ mice (t 50 ϭ 146 days) compared to TgT⌬N mice, most likely due to a background strain effect. Relatively, in TgT⌬N/RAG-2 Ϫ/Ϫ littermates the t 50 was again delayed (167 days), albeit to a lesser extent. A similar delay was also observed in p53 Ϫ/Ϫ RAG-2 Ϫ/Ϫ mice (t 50 ϭ 180 days) compared to p53 Ϫ/Ϫ RAG-2 ϩ/Ϫ mice (t 50 ϭ 165 days; Fig. 1B , Table 1 ).
V(D)J recombination is not required for T-cell tumorigenesis.
Since RAG-deficient mice harbor fewer thymocytes and are blocked in T-cell development (25, 37) , the observed delay and reduced frequency of thymoma may simply reflect a smaller and/or altered target cell population rather than a direct effect of V(D)J recombination. This could cause a dramatic effect, particularly when p53 is inactivated as a result of transgene expression, which may not occur in every cell. To circumvent these complications, T-cell development was rescued in TgT⌬N/RAG-1 Ϫ/Ϫ mice by thymocyte-specific expression of rearranged TCR␣ and TCR␤ transgenes (9) . Crosses with mice harboring lymphocytic choriomeningitis virus-specific TCR transgenes [TgN(TcrLCMV)] (33) were carried out as described in Materials and Methods. The effect of TCR transgenes on thymomagenesis in control TgT⌬N/TgTcr/ RAG-1 ϩ/Ϫ mice also served as a test for the role of V(D)J recombination, in that expression of rearranged TCR transgenes alone suppresses (though does not eliminate) V(D)J recombination (42) . Surprisingly, tumorigenesis was accelerated in TgT⌬N/TgTcr/RAG-1 ϩ/Ϫ mice (t 50 ϭ 110 days) relative to TgT⌬N/RAG-1 ϩ/Ϫ littermates (t 50 ϭ 165 days) (Fig. 2) . Hence, suppressed V(D)J recombination provided no deterrent to tumorigenesis. The reason for accelerated tumor development is unknown, but it could reflect increased target cell numbers or altered thymocyte proliferation. In support of this possibility, young (6-week-old) TgT⌬N/TgTcr/RAG-1 ϩ/Ϫ mice had an abnormally high percentage of thymocytes in S phase (22.9%), while nontransgenic and TgT⌬N S-phase thymocytes comprised only 8.8 and 8.9%, respectively, of the total population. Total apoptosis levels were unchanged (data not shown).
To measure the effect of complete inactivation of V(D)J recombination, TgT⌬N/TgTcr/RAG-1 ϩ/Ϫ mice were further backcrossed to RAG-1 Ϫ/Ϫ mice (see Materials and Methods). Importantly, RAG deficiency had no impact on the timing or frequency of tumorigenesis in TgT⌬N/TgTcr mice (Fig. 2) . All TgT⌬N/TgTcr/RAG-1 Ϫ/Ϫ mice developed thymic lymphoma within the same accelerated time frame (t 50 ϭ 101 days) as TgT⌬N/TgTcr/RAG-1 ϩ/Ϫ mice. The predominant cell type in each of three thymomas was CD4 CD8 DP, CD3 positive, and TCR␤ positive. This result shows that the increased latency and slightly reduced frequency of thymoma in RAG-deficient TgT⌬N mice was not due to the absence of V(D)J recombination. Since tumorigenesis was unaffected by complete absence of V(D)J recombination in the presence of T-cell maturation, the recombination process is not required for, nor No acceleration of T-cell tumorigenesis in a scid background. Although the foregoing studies show that V(D)J recombination is dispensable for thymoma development, it is possible that the recombination pathway, if present, plays a role that may be compensated for in its absence. This possibility seems unlikely given that the putative compensatory process would not rescue V(D)J recombination and would thus function by a different mechanism. Nonetheless, two approaches were used to test this possibility. In the first approach, tumorigenesis rates were tested in the scid background (8) . scid mice are defective in the DNA-dependent protein kinase activity required for rejoining of V(D)J coding DNA ends (12, 43) . As a result, scid lymphocytes accumulate V(D)J-associated DSBs. Thus, although the recombination overall is inhibited, the hypothesized signal to p53 would be increased. If such breaks provide secondary cooperating mutations for tumorigenesis in the absence of p53, thymoma development would be accelerated in this background. Indeed, previous studies showed that p53 Ϫ/Ϫ /scid mice died earlier than p53 Ϫ/Ϫ littermates (7, 15, 28) . However, because p53 was absent from all cells, these mice developed B-cell, as well as T-cell, lymphoma. In TgT⌬N mice, exclusive analysis of thymoma is possible. Consistent with results for the TgT⌬N/RAG Ϫ/Ϫ mice, development of thymic lymphoma was not accelerated in TgT⌬N/ scid mice ( Fig. 3A ; Table 1 ). Instead, tumorigenesis was slightly delayed in these mice (t 50 ϭ 210 days) compared to TgT⌬N/scid/wt mice (t 50 ϭ 183 days). To determine whether this effect was unique to the transgenic mice, p53
Ϫ/Ϫ /scid crosses were performed (Fig. 3B) . Again, thymomagenesis was clearly not accelerated. Although three of five p53 Ϫ/Ϫ /scid/wt mice developed thymoma within the usual time frame (t 50 ϭ 183 days), none of the p53 Ϫ/Ϫ /scid/scid mice developed thymoma. Rather, these mice died of other causes with a t 50 of 214 days (see the legend to Fig. 3 ). Because the number of p53 Ϫ/ Ϫ/scid/scid mice analyzed was small, this difference may not be statistically significant. However, lack of thymoma acceleration is consistent with what occurs in the TgT⌬N/scid/scid mice. The difference in these experiments compared with those reported previously is not clear but may be attributable to the difference in scid background strains used (see Discussion). The sciddependent delay observed here in TgT⌬N mice most likely reflects a reduced number of thymocytes as in RAG-deficient mice. Thus, these experiments show no evidence that increased V(D)J DSBs accelerate T-cell lymphoma development in the absence of p53.
Chromosome analysis of p53-deficient thymomas. As another test for participation of V(D)J recombination in p53-deficient thymic lymphoma, chromosomes of TgT⌬N thymomas were analyzed for evidence of translocations involving TCR loci. If flawed recombination events provide the signal for p53 tumor suppression, these events should contribute to tumorigenesis in the absence of p53 and would be identifiable in tumor cells. This is a reasonable expectation since tumorigenic translocations involving TCR or Ig genes occur in several human T-and B-cell neoplasms (20, 30, 35) . Furthermore, TCR translocations are readily observed with increased frequency in ataxia telangiectasia (AT) lymphoid malignancies (20, 39) a Trisomic chromosomes and translocations present in the majority of metaphases (Ն70%) are listed; less frequent chromosome duplications are in brackets. The frequencies of the aberrations are indicated in parentheses as number of cells with the aberration/total cell number examined. Sample TgT⌬N-8 contained double minute chromosomes. Average chromosome numbers are rounded to the nearest whole integer. The ranges of chromosome numbers in individual cells are also listed.
mice (4, 45) . Evidence suggests that ATM has a role in some p53 DNA damage-induced checkpoints (19) .
Karyotypes of nine TgT⌬N and three p53 Ϫ/Ϫ terminal thymomas were analyzed ( Table 2 ). Only three tumors harbored translocations in the majority of cells analyzed, and none of these involved the TCR-bearing chromosomes 6, 13, and 14. In contrast, aneuploidy, including abundant trisomy and some tetrasomy, was frequently observed. Although any of the 20 chromosomes could be affected, trisomy of chromosome 1, 4, 5, or 15 was frequently present (Table 2 ). Such specificity in chromosome aberrations may indicate the participation of oncogene amplification in thymoma development. Although these data are not sufficient to address the role of any given oncogene, several genes, including some (c-myc [2, 6] , lck [1] , and scl/tal1 [3, 21] ) known to play a role in T-cell tumorigenesis, are present on the selected chromosomes (Table 3) .
To be sure that karyotype analysis did not overlook TCR translocations not visibly detectable, we further analyzed tumors by chromosome painting. Metaphase spreads from seven a Twenty cells for each thymoma specimen were examined by using painting probes for chromosomes 6, 13, and 14 as described in Materials and Methods. tumors were painted with whole-chromosome probes for chromosomes 6, 13, and 14. None of these tumors showed evidence of TCR translocation, while a control ATM-deficient tumor showed a t(14;14) translocation in all cells examined ( Fig. 4 ; Table 4 ). Together with the genetic evidence described above, these studies indicate that V(D)J recombination does not participate significantly in p53-deficient thymomagenesis. The chromosome analysis also suggests that the mechanism for thymic lymphoma induction may be different for p53 deficiency than for ATM deficiency, in which case these factors function in distinct pathways in thymocyte tumor suppression. This notion is supported by the observation that thymoma development is more rapid in ATM Ϫ/Ϫ /p53 Ϫ/Ϫ mice than in mice harboring either single deficiency (44) .
DISCUSSION
Although previous data are consistent with the hypothesis that TCR gene recombination could be involved in p53-deficient T-cell tumorigenesis, studies presented here indicate that this process is not required. Inactivation of V(D)J recombination using RAG-deficient mice did not inhibit T-cell tumorigenesis predisposed by p53 deficiency. This was most evident in TgT⌬N/RAG-1 Ϫ/Ϫ mice in which T-cell maturation was rescued by expression of rearranged TCR␣ and -␤ transgenes. In that case, neither the timing nor the frequency of tumorigenesis was affected by the absence of V(D)J recombination relative to controls. Interestingly, expression of rearranged TCR genes in TgT⌬N mice accelerated T-cell tumorigenesis. Although initially surprising, the high S-phase thymocyte population associated with TCR transgene expression could account for this result. Neither p53 Ϫ/Ϫ nor TgT⌬N thymocytes proliferate above normal levels prior to overt thymoma, while thymoma cells have a high proliferative index (22a). Thus, proliferation of TCR transgene-expressing thymocytes may overcome the need for genetic events that stimulate this step in tumorigenesis. Regardless of the reason for acceleration of these tumors, they do not require V(D)J recombination. Thymoma developed in 100% of TgT⌬N/TgTcr mice, even though allelic exclusion substantially suppresses recombination. Moreover, further inactivation of V(D)J recombination by RAG deficiency had no effect on thymoma development. Recent studies by Nacht and Jacks (27) also concluded that V(D)J recombination was not required for p53 deficiency-induced thymoma. Their studies showed that a RAG deficiency in the p53 Ϫ/Ϫ background did not significantly alter tumor development in p53 Ϫ/Ϫ mice. In the absence of TCR transgene expression, RAG deficiency alone caused a delay in thymoma development, although these tumors occurred with a high frequency. This effect was most dramatic in TgT⌬N/RAG-1 Ϫ/Ϫ mice, which lived 44% longer than controls. The effect was not as dramatic in TgT⌬N/RAG-2 Ϫ/Ϫ or p53 Ϫ/Ϫ /RAG-2 Ϫ/Ϫ mice, although these mice lived longer (14 and 9%, respectively) than controls as well. In the study by Nacht and Jacks (27) , a RAG-1 deficiency did not significantly alter the survival time of p53 Ϫ/Ϫ mice. Thus, the delay we observed in TgT⌬N/RAG-1 Ϫ/Ϫ mice may be specific to the dependence on transgene expression for p53 inactivation. The altered thymocyte population caused by RAG deficiency could affect the percentage of cells expressing T⌬N. While we know that the majority of TgT⌬N thymocytes express T⌬N, we did not examine the TgT⌬N/RAG-1 Ϫ/Ϫ thymocytes for T⌬N expression. Our experiments using TCR transgenic mice support the conclusion that the delay in thymoma development was caused by the altered and/or reduced RAG-deficient thymocyte population. Expression of rearranged TCR transgenes in RAG-deficient mice is known to rescue the defect in mature T-cell production (9) , and in this background a RAG-specific delay in tumorigenesis is not observed. Since it is unlikely that expression of the TCR transgenes also completely alters the mechanism of thymomagenesis, we conclude that inactivation of V(D)J recombination has no impact on the development of thymoma induced by p53 deficiency.
Our studies with scid mice also support the notion that V(D)J DSBs associated with an inability to rejoin coding ends do not promote thymoma. In the homozygous scid background, we observed no acceleration of thymoma with either TgT⌬N or p53 Ϫ/Ϫ mice. This result was surprising since previous reports showed that p53 Ϫ/Ϫ scid/scid mice developed accelerated lymphoid malignancies compared to p53 Ϫ/Ϫ mice (15, 28) . In those studies, most mice (60 to 88%) developed predominantly B-cell lymphoma, although some T-cell lymphoma was observed. Thus, a high frequency of accelerated thymoma was not specifically observed. TgT⌬N mice develop only thymoma; survival of TgT⌬N mice homozygous at the scid locus is extended by 15%, and 62% of the mice develop thymoma. However, the difference in our study compared to previous reports was not specific to p53 inactivation by T⌬N, since the p53 Ϫ/Ϫ scid/scid mice in our study also showed no acceleration of death due to lymphoma. A plausible explanation for the difference between studies is that the scid mutation was in different genetic backgrounds-C.B-17 in previous studies and C57BL/6J here. Nacht et al. showed that the genetic background significantly affected the extent of lymphoma acceleration in p53 Ϫ/Ϫ scid/scid mice relative to controls, with the effect being more dramatic in a 129/Sv-C57BL6-C.B-17 background than in a C57BL6-C.B-17 background (28). The p53 Ϫ/Ϫ scid/scid mice generated in our study were entirely C57BL6, while the TgT⌬N scid/scid mice were C57BL6-DBA. In addition to having the defect in V(D)J recombination, scid mice are defective in general DNA repair mechanisms (8, 43) . In fact, the previous reports established that a DNA damageinducible p53 checkpoint is intact in scid mice (7, 15, 28) . Thus, it is possible that the acceleration of lymphoma previously observed reflects the absence of a general DNA damage checkpoint not specific to V(D)J recombination and that the level of damage, repair, or p53-independent checkpoint functions varies in distinct genetic backgrounds.
In this study, we also show that TCR translocations are not apparent in thymomas induced by a p53 deficiency. The chromosome painting analysis was performed blind, and the ATM Ϫ/Ϫ thymoma was readily characterized as harboring a TCR translocation. None of the other thymomas analyzed (all of which were induced by p53 deficiency) carried a TCR translocation detectable by this method. Chromosome painting is not sensitive enough to detect small deletions or insertions (34) , and so we cannot rule out that aberrant rearrangement of TCR loci occurred at some level. However, this method readily detected a high frequency of TCR translocations in thymomas from ATM Ϫ/Ϫ mice (4). Thus, if TCR aberrations are involved in p53-deficient thymoma, the mechanism appears to be distinct from that caused by an ATM deficiency. Together with the genetic data described above, the chromosome analysis indicates that V(D)J recombination does not play a substantial role in thymomagenesis induced by p53 deficiency.
The observation that V(D)J recombination is not required for p53-deficient thymomagenesis is surprising since DNA damage-induced apoptosis of thymocytes has been considered the basis for tumor suppression in this cell type. Given that a high frequency of p53 Ϫ/Ϫ mice and all TgT⌬N mice spontane-ously develop thymic lymphoma, thymocytes clearly need p53 tumor suppression for normal homeostasis. Perhaps T cells are susceptible to more general forms of DNA damage at some developmental stages. Alternatively, it is possible that the natural p53 signal does not involve DNA damage in these cells. Many aberrant conditions, including cell growth disruption, oxidative stress, and altered metabolic pools, induce p53 function in other cell types (see reference 22 for a review). The challenge now is to determine which, if any, of these conditions contributes to p53 tumor suppression in T cells. Although p53 is not required for apoptosis associated with clonal deletion of T cells (11, 23, 24) , it could be required for apoptosis induced by an as yet unknown stimulus. Alternatively, p53 tumor suppression in thymocytes may involve a growth arrest checkpoint function in addition to, or instead of, apoptosis. For example, the consistent presence of aneuploidy in p53-deficient thymoma may indicate that loss of p53 checkpoint regulation leading to genetic instability has a key role in this tumor type.
